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Abstract
Background: In early (T1) oesophageal adenocarcinoma (OAC), the histological profile of an endoscopic resection specimen
plays a pivotal role in the prediction of lymph node metastasis and the potential need for oesophagectomy with
lymphadenectomy.
Objective: To evaluate the inter-observer agreement of the histological assessment of submucosal (pT1b) OAC.
Methods: Surgical and endoscopic resection specimens with pT1b OAC were independently reviewed by three gastrointes-
tinal pathologists. Agreement was determined by intraclass correlation coefficient for continuous variables, and Fleiss’
kappa (k) for categorical variables. Bland–Altman plots of the submucosal invasion depth were made.
Results: Eighty-five resection specimens with pT1b OAC were evaluated. The agreement was good for differentiation grade
(k¼0.77, 95% confidence interval (CI) 0.68–0.87), excellent for lymphovascular invasion (k¼0.88, 95% CI 0.76–1.00) and
moderate for submucosal invasion depth using the Paris and Pragmatic classifications (k¼0.60, 95% CI 0.49–0.72 and
k¼0.42, 95% CI 0.33–0.51, respectively). Systematic mean differences between pathologists were detected for the meas-
urement of submucosal invasion depth, ranging from 297 mm to 602 mm.
Conclusions: A substantial discordance was found between pathologists for the measurement of submucosal invasion depth
in pT1b OAC. Differences may lead to an over- or underestimation of the lymph node metastasis risk, with grave implications
for the treatment strategy. Review by a second gastrointestinal pathologist is recommended to improve differentiating
between a favourable and an unfavourable histological profile.
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Key summary
Established knowledge on this subject:
. The histological proﬁle of an endoscopic resection specimen plays a pivotal role in the prediction of lymph
node metastasis (LNM) in early (T1) oesophageal adenocarcinoma (OAC).
. Patients with a mucosal OAC can be treated curatively by endoscopic resection, the risk for LNM being
considered negligible.
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. Patients with a submucosal OAC are generally advised to undergo oesophagectomy with lymphadenect-
omy for the presumed risk of LNM.
. New studies now cautiously propose a conservative policy with surveillance after endoscopic resection for
low-risk submucosal OAC, given that the risk of LNM remains low.
New ﬁndings:
. There is good to excellent agreement between pathologists for the histological assessment of diﬀerenti-
ation grade and lymphovascular invasion.
. There is a substantial discordance between pathologists for the assessment of submucosal
invasion depth in OAC, highlighting the practical diﬃculties associated with the measurement of this
parameter.
. The found discordance may potentially lead to an over- or underestimation of the LNM risk, with grave
implications for the treatment strategy of choice.
Introduction
In the past three decades, the incidence of oesophageal
adenocarcinoma (OAC) has risen more rapidly than
any other malignant neoplasm in the western
world.1,2 Radical oesophagectomy has long been the
cornerstone treatment for OAC or high-grade dysplasia
in Barrett’s oesophagus, with mortality rates ranging
from 0% to 22%, and morbidity rates of up to 80%.3
In current clinical practice, however, minimally invasive
endoscopic treatment modalities have been widely
accepted and integrated into the management of
Barrett’s oesophagus and early (T1) OAC. A major
drawback of these endoscopic procedures, however, is
the inability to perform lymphadenectomy. Surgery is
advocated when the risk of lymph node metastasis
(LNM) outweighs the risk for mortality associated
with oesophagectomy.4–6
The histological proﬁle of an endoscopic resection
specimen plays a pivotal role in assessing the risk of
LNM in early (T1) OAC. Endoscopic resection was
initially only accepted for tumours that were limited
to the mucosa, based on the premise that the risk of
LNM in these superﬁcial lesions is negligible. However,
more recent publications have shown that when the
tumour extends into the submucosa with a maximum
invasion depth of 500 mm (sm1), in combination with a
well to moderate grade of diﬀerentiation (G1/G2) with-
out lymphovascular invasion (LVI), the risk of LNM
remains low.7–13 Hence, for these low-risk sm1 OACs,
multiple studies now cautiously propose a conservative
approach with surveillance after endoscopic resec-
tion.9,11–14 Guidelines in fact consider it a valid alter-
native for patients with a high surgical risk.4,15,16 An
accurate and reproducible histological assessment of
submucosal OAC is therefore essential, when this is
the fundament on which the appropriate treatment
strategy is determined.
The depth of invasion in the submucosa was ori-
ginally classiﬁed by subdividing the submucosa into
three equal layers (sm1/sm2/sm3). This so-called
Pragmatic classiﬁcation was developed based on
oesophagectomy specimens.17 In endoscopic resection
specimens, however, this classiﬁcation may not be
reliable, as subtotal resection of the submucosa
may lead to over-staging. This led to the develop-
ment of a quantitative classiﬁcation where submuco-
sal invasion was measured in micrometres, with sm1
deﬁned as invasion depth of 500 mm and sm2/3 as
invasion depth of >500 mm (Paris classiﬁcation).7,18
Although this new classiﬁcation has already
been integrated into current clinical practice,19 the
agreement of this classiﬁcation has not been
determined.
Diﬀerentiation grade and LVI are two other histo-
logical characteristics associated with the risk of LNM
in submucosal OAC. A high inter-observer variation
was detected for these parameters in earlier studies on
breast and colorectal cancer.20–23 To date, the agree-
ment for the assessment of these parameters in OAC
has not been investigated.
The aim of this study was to determine the agree-
ment between pathologists for the histological assess-
ment of submucosal OAC, which includes the depth of
submucosal invasion, diﬀerentiation grade and the
presence of LVI.
Materials and methods
Study design and patients
We conducted a retrospective cohort study, including
patients from a tertiary referral centre in The
Netherlands. All consecutive patients who underwent
an oesophagectomy or endoscopic resection for a patho-
logically staged submucosal (pT1b) OAC between 1989
and 2014 in the Erasmus University Medical Centre
were identiﬁed using the Registry of the Netherlands
Comprehensive Cancer Organization. Patients
were included when pT1b OAC was reported in the ori-
ginal pathology report. Patients were excluded when
treated by neoadjuvant chemo- and/or radiation ther-
apy, or when histopathology was unavailable for
revision.
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Histopathological evaluation
After eligible patients were identiﬁed, hematoxylin and
eosin stained (H&E) slides and formalin-ﬁxed paraﬃn-
embedded (FFPE) tissue blocks of the resection speci-
men were retrieved from the archives of the department
of pathology. All samples were independently reviewed
by three gastrointestinal (GI) pathologists from the
Erasmus University Medical Centre, who were blinded
from the original diagnosis and clinical outcome (devel-
opment of LNM), as well as from each other’s results.
Submucosal invasion depth. All H&E-stained slides were
initially reexamined by one pathologist to verify that
there was submucosal invasion, and to identify the
slide and corresponding FFPE block with the deepest
invasion of tumour in the submucosa. Subsequently,
immunohistochemistry (IHC) using desmin and pan-
keratin (D&P) double staining was done to highlight
the lamina muscularis mucosae as well as the adenocar-
cinoma. The H&E and D&P-IHC slides were digitally
scanned and made available for review to three GI
pathologists. Measurements on submucosal invasion
depth were done in both the H&E and D&P-IHC
slides respectively.
The deepest level of submucosal invasion was mea-
sured in micrometres (mm), measured from below the
lamina muscularis mucosa (Figure 1). Where the
lamina muscularis mucosae was duplicated, submuco-
sal invasion was measured from the deepest layer.24
Based on the invasion depth in mm, the Paris classiﬁca-
tion was derived (sm1 invasion 500mm; sm2/3
invasion> 500 mm).
In order to determine the Pragmatic classiﬁcation,
the total thickness of the submucosa was additionally
measured in mm. In surgical resection specimens this
was measured at the point of deepest submucosal
tumour invasion, and in endoscopic resection speci-
mens this was measured adjacent to the tumour. The
Pragmatic classiﬁcation was derived by correlating the
depth of submucosal tumour invasion with the total
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Figure 1. Histological assessment of pT1b OAC, scored independently by three gastrointestinal pathologists. (a) Surgical resection
specimen, stained by hematoxylin and eosin: all three pathologists scored a moderate grade of differentiation (G2) and no lymphovascular
invasion (LVI). Submucosal invasion depth for pathologist 1 (P1) was 1720 mm, pathologist 2 (P2) was 1525 mm and pathologist 3 (P3) was
1890 mm. (b) Endoscopic resection specimen, with desmin and pankeratin immunohistochemistry: all three pathologists scored no LVI. The
grade of differentiation was moderate for P1, good for P2 and moderate for P3. Submucosal invasion depth for P1 was 581 mm, P2 was
340 mm and P3 was 620 mm.
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submucosal thickness, where the submucosa was sub-
divided into three equal layers (sm1/sm2/sm3).
Grade of differentiation and LVI. Grade of diﬀerentiation
and presence of LVI were assessed independently by the
same three pathologists. For these parameters, whole
case H&E slide sets were re-examined by microscopy.
Grading was classiﬁed according to the World Health
Organization classiﬁcation for colorectal adenocarcin-
oma21 and included G1: well diﬀerentiated, G2: mod-
erately diﬀerentiated, G3: poorly diﬀerentiated, G4:
undiﬀerentiated. LVI was scored as being either present
or absent.
Combination of histological characteristics. Histological
characteristics of the tumours were combined and clas-
siﬁed as ‘favourable’ or ‘unfavourable’. Favourable was
deﬁned as submucosal invasion depth of 500mm (sm1
according to the Paris classiﬁcation), G1 or G2 and no
LVI. Unfavourable was deﬁned as any poor histo-
logical characteristic, such as submucosal invasion
depth of >500 mm (sm2/3 according to the Paris classi-
ﬁcation), G3 or G4 or the presence of LVI.
Clinical follow-up
The primary clinical endpoint for patients in this study
was the development of LNM, as this is the main cause
for concern in patients with submucosal OAC. After
oesophagectomy with lymph node dissection, a thresh-
old of at least 12 lymph nodes was used to assess the
lymph node status.25 However, due to diﬀerent surgical
resection techniques over time with less extensive lym-
phadenectomy, the development of suspected LNM
during follow-up, either pathologically conﬁrmed or
not, was used as a surrogate endpoint for LNM. This
surrogate endpoint was also used for patients that were
treated by primary endoscopic resection only. Patient
charts were assessed to review the clinical follow-up.
The date of established LNM and the date of the last
known clinical follow-up were recorded.
Statistical analysis
Statistical analysis was performed using SPSS software
(version 21, SPSS Inc., Chicago, Illinois, USA),
and RStudio Team (2016; RStudio: Integrated
Development for R. RStudio, Inc., Boston,
Massachusetts, USA, version 1.0.44). For categorical
variables, the observed agreement was summarized as
a percentage agreement between the three pathologists.
The degree of agreement was determined using the
Fleiss’ kappa (k) for categorical variables and intraclass
correlation coeﬃcient (ICC) for continuous variables.
Coeﬃcients< 0.21, 0.21–0.40, 0.41–0.60, 0.61–0.80 and
0.81–1.00 represent a poor, fair, moderate, good and
excellent agreement, respectively.26 Corresponding
95% conﬁdence intervals (95% CI) were calculated.
Continuous variables were plotted in a Bland–Altman
plot in order to assess for systematic diﬀerences
between pathologists.
Results
Patients
A total of 89 patients with a pT1b OAC were identiﬁed.
Four patients were excluded because the H&E slides
and FFPE material were not available (three patients)
or were of poor quality (one patient). Hence, 85
patients with a pT1b OAC were included in this
study. An endoscopic resection had been performed
in 35/85 patients (41%) and 50/85 patients (59%)
were treated by primary oesophagectomy. Patient char-
acteristics are shown in Table 1.
In 74/85 patients (87%) the clinical follow-up con-
cerning LNM was known. LNM had occurred in 24/74
patients (33%) with pT1b OAC, found either in surgi-
cally resected specimens (21 patients) or during follow-
up (three patients). The median follow-up time was
4.98 years (interquartile range 2.8–5.9 years).
In 11/85 patients (13%) the LNM status during
follow-up was unknown. In nine patients this was
because of loss to follow-up after resection, one patient
was treated by chemotherapy for a second primary
tumour, and one patient had a second primary
tumour with LNM of unknown origin.
Tumour characteristics of the 85 patients included in
the study are shown in Supplementary Material Table 1
online.
Table 1. Patient characteristics of the 85 patients with a sub-
mucosal oesophageal adenocarcinoma.
Gender, male, n (%) 69 (81)
Age at resection, median (range), years 66 (41–85)
Treatment regime
Endoscopic resection, n (%) 35 (41)
Primary surgery, n (%) 50 (59)
Surgical approach
Transhiatal oesophagectomy, n (%) 45 (90)
Transthoracic oesophagectomy, n (%) 3 (6)
Gastrectomy, n (%) 1 (2)
Unknown, n (%) 1 (2)
Lymph node metastasis during follow-upa 24 (33)
Continuous data is presented as median (range). Categorical data as n (%).
aKnown in only 74 (87%) patients.
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Histopathological assessment
Submucosal invasion depth. There was a good degree of
agreement between pathologists for the assessment of
the depth of tumour invasion in micrometres
(ICC¼ 0.649, 95% CI 0.536–0.746) and an overall
good degree of agreement for the assessment of the
submucosal thickness (ICC¼ 0.659, 95% CI 0.543–
0.755) (Table 2).
When the Paris and Pragmatic classiﬁcation for sub-
mucosal invasion depth were derived from these meas-
urements, there was agreement between pathologists in
69/85 patients (82%) and 40/84 patients (47%) respect-
ively, with a moderate degree of agreement (k¼ 0.603,
95% CI 0.489–0.717; k¼ 0.419, 95% CI 0.333–0.505)
(Table 2).
Importantly, when comparing measurements of sub-
mucosal invasion depth, signiﬁcant diﬀerences were
found between pathologists. See Figure 1 for a repre-
sentative example of how pathologists measured sub-
mucosal invasion depth diﬀerently. Between
pathologists 1 and 2 there was a systematic mean dif-
ference of 297mm (p¼ 0.073), between pathologists 1
and 3 this was 304 mm (p¼ 0.065) and between patholo-
gists 2 and 3 this was 602 mm (p< 0.0001) (Figure 2,
Table 3). The discordance was further supported by
Bland–Altman plots (Figure 2), where a funnel-
shaped trend between the measurements of the diﬀerent
pathologists was seen. As the mean invasion depth
increased, the diﬀerence in measurement of submucosal
invasion depth between pathologists became larger. In
other words, smaller diﬀerences were observed in
superﬁcial tumours, and larger diﬀerences were
observed for deeper tumours.
Additional D&P-IHC could be performed in 52/85
patients (61%). In the remaining 33 patients, FFPE
blocks were not available, were of poor quality or the
invasive component was not present after sectioning.
The agreement between pathologists for the assessment
of submucosal invasion depth in D&P-IHC, was com-
parable to the results derived from H&E slides, as seen
in Supplementary Material Table 2 Online. The agree-
ment for both the Paris and Pragmatic classiﬁcations
did not improve by usage of D&P-IHC.
Grade of differentiation and LVI. For the assessment of
grade of diﬀerentiation, agreement between patholo-
gists was seen in 68/85 patients (80%), with a good
degree of agreement (k¼ 0.774, 95% CI 0.680–0.868).
For the assessment of LVI, agreement between path-
ologists was seen in 80/85 patients (94%), with an excel-
lent degree of agreement (k¼ 0.879, 95% CI 0.756–
1.002) (Table 2).
Combination of histological characteristics. Agreement
between pathologists for favourable or unfavourable
histological characteristics was seen in 76/85 patients
(89%), with a good degree of agreement (k¼ 0.728,
95% CI 0.605–0.851) (Table 2). The tumour was clas-
siﬁed as unfavourable in 67/76 patients (88%) and
favourable in 9/76 patients (12%).
In 66/76 patients (87%) the clinical follow-up con-
cerning LNM was known. The tumour was classiﬁed as
unfavourable in 58/66 patients (88%), and 24/58
Table 2. Inter-observer agreement between three gastrointestinal pathologists, for the histological assessment of pT1b oesophageal
adenocarcinoma in 85 patients. The histological parameters were established using hematoxylin and eosin stained slides.
Histological parameter (continuous variable) n
Observed
agreement ICC 95% CI Interpretation
Submucosal invasion in mm 85 N/A 0.657 (0.547–0.750) Good
Total thickness of submucosa in mm 84 N/A 0.659 (0.543–0.755) Good
35 (ER) N/A 0.704 (0.515–0.833) Good
49 (surgical) N/A 0.553 (0.389–0.698) Moderate
Histological parameter (categorical variable) n
Observed
agreement
Fleiss’
kappa 95% CI Interpretation
Paris classification 85 82% 0.603 (0.489–0.717) Moderate
Pragmatic classification 84 47% 0.419 (0.333–0.505) Moderate
Tumour differentiation 85 80% 0.774 (0.680–0.868) Good
LVI 85 94% 0.879 (0.756–1.002) Excellent
Combined histological characteristicsa 85 89% 0.728 (0.605–0.851) Good
aFavourable: pT1a/sm1, G1/2, and no lymphovascular invasion (LVI); unfavourable: pTsm2/3/pT2, or G3/4, or LVI.
N/A: not applicable; ICC: intraclass correlation coefficient; CI: confidence interval; ER: endoscopic resection.
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patients (41%) developed LNM. In contrast, no LNM
developed in the 8/66 patients (12%) that were classi-
ﬁed as favourable.
Disagreement between pathologists for favourable
or unfavourable histological characteristics was seen
in 9/85 patients (11%). In all these patients, the
disagreement concerned the Paris classiﬁcation of
tumour depth (sm1 invasion 500 mm or sm2/3
invasion> 500 mm). It was agreed that all other
characteristics were favourable, such as a G1 or G2
and no LVI. In 8/9 (89%) patients the clinical fol-
low-up concerning LNM was known and none devel-
oped LNM.
Discussion
In early (T1) OAC, the risk for LNM is predicted based
on the histological proﬁle of an endoscopic resection
specimen. An accurate and reliable histological assess-
ment is crucial when this is the fundament on which the
appropriate treatment strategy is determined. In this
study on patients with submucosal OAC, we found
that there was a good to excellent degree of agreement
between GI pathologists for the assessment of the dif-
ferentiation grade and the presence of LVI. However,
we did detect a signiﬁcant discordance between path-
ologists for the measurement of submucosal invasion
depth, which highlights the practical diﬃculties asso-
ciated with the assessment of this parameter. This is a
highly relevant observation, given the decisive nature of
the 500 mm cut-oﬀ level, where surveillance is recom-
mended for 500 mm invasion and additional
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Figure 2. Bland-Altman plots, illustrating systematic mean differences between pathologists for the measurement of submucosal
invasion depth. Differences between measurements were plotted against the mean of two measurements. The mean difference between
pathologists is represented by the parallel line adjacent to the 0-line in the x-axis. A: mean difference of submucosal invasion depth is
297 mm (p¼ 0.073), B: mean difference of submucosal invasion depth is 304 mm (p¼ 0.065), C: mean difference of submucosal invasion
depth is 602 mm (p< 0.05). Please note the funnel-shaped trend between the pathologists; as the mean invasion depth increased,
differences in measurement of invasion depth became more prominent.
Table 3. Systematic mean differences between pathologists for
the measurement of submucosal invasion depth.
Mean difference
in measurement
of submucosal
invasion depth (mm) p-value 95% CI
Pathologist 1 vs.
pathologist 2
297 0.073 (3254; 2659)
Pathologist 1 vs.
pathologist 3
304 0.065 (2637; 3246)
Pathologist 2 vs.
pathologist 3
602 0.00002 (1768; 2972)
CI: confidence interval.
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oesophagectomy with lymphadenectomy is recom-
mended for invasion depth of >500 mm.4,9,11–16
The agreement for submucosal invasion depth alone
was good (ICC¼ 0.649). However, when the Paris clas-
siﬁcation for tumour depth invasion was derived, the
agreement between pathologists became moderate
(k¼ 0.603). This aggravation can be explained by the
systematic discordance in measurement between path-
ologists, ranging between 297mm and 602 mm, which is
of great impact for values in close proximity to the
500 mm cut-oﬀ level. The inter-observer variation was
even higher for the Pragmatic classiﬁcation (k¼ 0.419),
which may be explained by the fact that a kappa value
tends to be lower with increasing number of cate-
gories.27 Another explanation may be the fact that we
calculated the invasion category by correlating two
continuous variables, each with its own variation,
whilst in clinical practice this classiﬁcation is often
made by eyeballing. In a previous inter-observer agree-
ment study on the combined assessment of mucosal and
submucosal OAC, the Pragmatic classiﬁcation was also
found to be moderate.28 Although both classiﬁcations
should be used for clinical decision making,7,29 we
cannot reliably demonstrate superiority of either
system in terms of agreement. Moreover, D&P-IHC
did not substantially improve agreement in Paris and
Pragmatic classiﬁcations. A consensus assessment by a
second GI pathologist may be of added value for pT1b
lesions with submucosal invasion in close proximity to
500 mm cut-oﬀ.
The substantial discordance found in this study may
be explained by subjective anticipation of the deepest
invasion, but also by several practical diﬃculties asso-
ciated with the measurement of submucosal invasion.
These include specimen curling and associated arte-
facts, which may make it diﬃcult to assess the orienta-
tion plane and area of deepest invasion. Additionally,
morphologic characteristics of the muscularis mucosa,
such as the presence of a discontinuous or hypertrophic
muscularis mucosa, the presence of a duplicated mus-
cularis mucosa or destruction by the carcinoma, could
further impair a valid assessment (Figure 1). These
properties of the muscularis mucosa, but also the
method of measurement (from the bottom of the mus-
cularis mucosa or from an imaginary line of muscularis
mucosa in the case of a discontinuous muscularis
mucosa) have been named as a cause of discrep-
ancy.30,31 Tissue preservation in this retrospective
study might also have had an impact on the slide qual-
ity and accuracy of assessment.
The validity of the 500 mm cut-oﬀ for the prediction
of LNM has been challenged in various gastric cancer
studies, but also in colorectal cancer studies where a
cut-oﬀ of 1000mm is used.30–33 Historically, the quan-
titative cut-oﬀ was determined based on surgical
resection specimens; however, specimen handling
could artiﬁcially aﬀect the depth of invasion.
Stretching of the specimen after resection could
decrease the thickness of the submucosa32 and inad-
equate pinning of the specimen before rapid ﬁxation
may lead to submucosal shrinkage.33 Our results on
the discordant measurement between pathologists
form an additional important argument to question
the validity of the 500 mm cut-oﬀ for the prediction
of LNM.
Our results on the agreement for diﬀerentiation
grade (k¼ 0.774) and LVI (k¼ 0.879) are in contrast
with previous studies in breast and colorectal cancer.
These studies reported a moderate inter-observer agree-
ment for diﬀerentiation grade20–22 and a substantial
variability for LVI.23 A possible explanation is that
the pathologists involved in this study are highly experi-
enced, and all from the same centre, with a close col-
laboration over the years.
Clinical management decisions are made based on
the combined histological proﬁle of a pT1b OAC.
Our results show a good degree of agreement
(k¼ 0.728) between pathologists when tumours were
classiﬁed as favourable or unfavourable. All patients
that developed LNM had tumours that the pathologists
agreed were unfavourable, and no LNM developed in
patients with tumours that the pathologists agreed were
favourable. This supports the proposed shift to a con-
servative policy after endoscopic resection when
favourable characteristics are found. Where there was
disagreement between pathologists (11%), this always
concerned the Paris classiﬁcation of tumour depth.
Fortunately, no LNM was found in these patients.
We should caution the validity of the 500 mm cut-oﬀ;
however, considering no LNM was found, we may also
be less apprehensive of the clinical consequence.
Ultimately, reliable conclusions on the correlation
with LNM cannot be made based on our small
sample size. It is also questionable whether histological
data from surgical and endoscopic resection specimens
combined are comparable for the prediction of LNM.
Specimen handling and diﬀerent sectioning intervals
between endoscopic resection and surgical specimens
(2mm vs. 5mm) may result in an underestimation of
the deepest invasion in surgical resection specimens.
The strength of this study is that, for the ﬁrst time,
the quantitative assessment for submucosal invasion
depth in early OAC is analysed systematically, high-
lighting the practical diﬃculties and inaccuracy asso-
ciated with the measurement of this parameter. Other
strengths include the assessment of a large cohort of
patients with submucosal OAC and the blinding of
GI pathologists involved in this study. This study also
has limitations. The involved pathologists were all from
the same centre, having learned from each other over
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the years. Additionally, the intra-observer agreement
was not evaluated. Due to the retrospective study
design, the clinical follow-up on LNM was less standar-
dized and patients were also lost to follow-up.
In conclusion, there is a good to excellent degree of
agreement for the histological assessment of diﬀerenti-
ation grade and LVI in submucosal OAC. However, for
the measurement of submucosal invasion depth, sub-
stantial diﬀerences exist between pathologists. This
potentially leads to an over- or underestimation of the
LNM risk, with grave implications on the treatment
strategy of choice. In the current innovative climate,
where we explore the limits to endoscopic therapy in
patients with early OAC, this is a highly relevant issue
to be aware of.
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